Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation.

@article{Charman1993BiopharmaceuticalCO,
  title={Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation.},
  author={William Neil Charman and Susan A. Charman and Donald C. Monkhouse and Steven Edgar Frisbee and Euan A Lockhart and Sarah Weisman and Garret A. FitzGerald},
  journal={British journal of clinical pharmacology},
  year={1993},
  volume={36 5},
  pages={
          470-3
        }
}
The release of aspirin from a 75 mg controlled-release formulation, designed to inhibit maximally thromboxane A2 production while sparing stimulated prostacyclin biosynthesis, was characterised in healthy subjects. The calculated in vivo release rate of aspirin matched the design goal of approximately 10 mg h(-1). The C(max) of aspirin associated with the controlled-release formulation was lowered 15-fold relative to a solution formulation of the same dose. The bioavailability of aspirin (based… CONTINUE READING
BETA